Current Value of Holding

$162 Million

Shares

3.86 Million

% of Portfolio

0.47%

Average Buy Price

$43.6

Avg closing price
Price range

4 Sands Capital Ultragenyx Pharmaceutical Trades

Sands Capital acquired 3.86 Million Ultragenyx Pharmaceutical shares worth $162 Million. That's 0.47% of their equity portfolio (39th largest holding). The investor owns 4.56% of the outstanding Ultragenyx Pharmaceutical stock. The first Ultragenyx Pharmaceutical trade was made in Q2 2023. Since then Sands Capital bought shares one more times and sold shares on two occasions. The investor's estimated purchase price is $168 Million, resulting in a loss of 4.0%.

Avg closing price
Price range
Sold 6.3% shares (-259 Thousand shares) Q1 2024
Avg closing price $47.17
Price range $43.02 - $53.69
Increased shares by 59.8% (+1.54 Million shares) Q4 2023
Avg closing price $38.77
Price range $31.73 - $49.19
Sold 3.6% shares (-96.4 Thousand shares) Q3 2023
Avg closing price $39.62
Price range $34.92 - $46.66
New holding (+2.67 Million shares) Q2 2023
Avg closing price $46.38
Price range $37.35 - $52.15

News about Ultragenyx Pharmaceutical Inc. and Sands Capital

Embed chart

Easily embed the chart on your blog or website – it will always update automatically!